Abstract 180P
Background
Circadian rhythms (CRs) are crucial biological processes that influence various physiological functions in humans. Previous studies from our team have shown that chronic circadian disruption, specifically chronic jetlag (CJL), increases tumor burden in a mouse melanoma model. The tumor immune microenvironment plays a complex regulatory role in tumorigenesis. However, the specific immune cell functions regulated by circadian disruption to promote tumor progression remain largely undefined. This study aims to demonstrate the critical role of NK cells in the innate immune system during circadian disruption across various mouse models.
Methods
We utilized three distinct mouse models representing varying immune states: C57BL/6 mice, NOD-SCID mice (lacking T/B cells), and B-NDG mice (lacking T/B/NK cells), melanomas were inoculated subcutaneously. Light was manipulated to modulate the circadian clock. Mice were maintained under normal light-dark environment (LD) or CJL environment (6-hour advance of the LD12:12 cycle every 2 days). We use RNA-seq, flow cytometry and quantitative immunofluorescence to analysis tumor immune microenvironment.
Results
Our findings indicate that tumor growth rates significantly increased under CJL in C57 and NOD-SCID mice compared to normal light-dark schedules. In contrast, the tumor growth rate difference between the two rhythm patterns disappeared in NK-cell-deficient B-NDG mice. Flow cytometry analysis revealed that in C57 mice, CJL led to an increase in CD8+ T cells and a decrease in NK cells in tumors, with similar trends observed in the spleen. Additionally, RNA-seq data indicated that CJL inhibits pathways related to both innate and adaptive immunity in tumors, significantly downregulating NK cell function pathways.
Conclusions
These data demonstrate that chronic circadian disruption promotes tumor progression by altering the tumor immune microenvironment, with changes in NK cell quantity and function playing a pivotal role in CJL's effects on tumor growth.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract
77P - A new prognostic index for patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab
Presenter: MARA PERSANO
Session: Poster Display session
Resources:
Abstract
79P - Relevance of combined positive score (CPS) & low-dose immune checkpoint inhibitors (ICIs) in microsatellite stable (MSS) advanced gastric adenocarcinoma (GC): A multi-institution analysis
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
80P - Tumor markers evolution in pts treated with TCE and association with radiologic response
Presenter: Constance d'Abrigeon
Session: Poster Display session
Resources:
Abstract
81P - Predictive value of inflammatory ratios on the outcome of advanced melanoma patients treated with anti-PD1 monotherapy: A multicentric analysis
Presenter: Aleksandar Popovic
Session: Poster Display session
Resources:
Abstract
82P - Predictive biomarkers for neoadjuvant immunochemotherapy efficacy in locally advanced cancer patients: A retrospective analysis based on changes in tumor shrinkage rate and lymphocyte count
Presenter: Zhanjie Zhang
Session: Poster Display session
Resources:
Abstract
83P - Effectiveness and safety of neoadjuvant immunochemotherapy with and without surgery in patients with resectable esophageal squamous cell carcinoma: A retrospective cohort study
Presenter: xuqiang liao
Session: Poster Display session
Resources:
Abstract
84P - Safety Of Treatment With Immune Checkpoint Inhibitors In Older Adults With Non-Small Cell Lung Cancer
Presenter: Verene Dougoud-Chauvin
Session: Poster Display session
Resources:
Abstract
86P - Treatment trajectories and outcome following irAE related hospitalization in metastatic cancer patients
Presenter: Veera Nurmela
Session: Poster Display session
Resources:
Abstract
87P - Access to vedolizumab for the management of immune-related colitis (IRC): A United Kingdom study
Presenter: Faye Coe
Session: Poster Display session
Resources:
Abstract